Athenagen, a biotech start-up in South San Francisco focused in the area of neurovascular diseases, said it has raised $50 million through a Series B financing.

The funds will be used primarily to advance development of the company’s lead programs targeting Alzheimer’s disease, age-related macular degeneration (AMD) and cognition enhancement, the company said.

The financing was co-led by Sanderling Ventures and Clarus Ventures, with a significant investment also made by Index Ventures. Current investors, Charter Life Sciences and Astellas Venture Management, also participated in the round. As a result of the financing, Dennis Henner, Ph.D., a Managing Director of Clarus Ventures, will take a seat on Athenagen’s board of directors, the company said.